Skip to main content
Caplight Logo









GeneMedicine

GeneMedicine

Private
SeoulHealthcare & Life Scienceshttps://gene-medicine.com

Last Round

Series C

May 20, 2025

Total Funding Raised

$40.7M

Company Overview

GeneMedicine operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in July 2021.

GeneMedicine is a biotechnology company that develops oncolytic virus and gene therapeutic platforms for the treatment of intractable cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

GeneMedicine Comparables

Compare GeneMedicine with similar companies based on industry and business-model similarity.

GeneMedicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lokon Pharma
81%
Valo Therapeutics
81%
TILT Biotherapeutics
80%
Book a demo to see all comparables

For institutional investors. Book with your work email.

GeneMedicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 20, 2025
Series BJul 1, 2021
Series AMay 1, 2019
SeedDec 1, 2018
Corporate FundingJul 1, 2016
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

GeneMedicine Investors

Notable investors and investment history

GeneMedicine investors
InvestorRounds
Bluepoint PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 143% MoM, reaching 2.9K.

  • Apr 3, 2026

    Monthly visitors increased 31% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

GeneMedicine Filings

Explore SEC and related filing metadata, where available.

GeneMedicine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about GeneMedicine's valuation, stock price, and market status.

Is GeneMedicine a public or private company?

GeneMedicine is a private company.

What is the current stock price of GeneMedicine?

GeneMedicine is a private company, so its shares have no public market price. Caplight tracks GeneMedicine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is GeneMedicine worth (valuation)?

Valuation information for GeneMedicine is not publicly available.

Can I buy GeneMedicine stock?

GeneMedicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was GeneMedicine's last funding round?

GeneMedicine's most recent funding round was Series C on May 20, 2025.

Who are the main investors in GeneMedicine?

Key investors in GeneMedicine include Bluepoint Partners.

Will GeneMedicine IPO soon?

No public IPO plans have been announced for GeneMedicine.

How can I track GeneMedicine secondary market activity?

Caplight tracks bids, offers, and trades in GeneMedicine's shares on secondary markets.

Firmographic Details

HeadquartersSeoul
Employee Range10
Year Founded2014
Last FundingMay 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?